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The emergence of multidrug resistance among Acinetobacter baumannii is leading to an increasing depen-
dence on the use of polymyxins as last-hope antibiotics. Here, we utilized genetic and biochemical methods to
define the involvement of the pmrCAB operon in polymyxin resistance in this organism. Sequence analysis of
16 polymyxin B-resistant strains, including 6 spontaneous mutants derived from strain ATCC 17978 and 10
clinical isolates from diverse sources, revealed that they had independent mutations in the pmrB gene, encoding
a sensor kinase, or in the response regulator PmrA. Knockout of the pmrB gene in two mutants and two clinical
isolates led to a decrease in the polymyxin B susceptibility of these strains, which could be restored with the
cloned pmrAB genes from the mutants but not from the wild type. Reverse transcription-quantitative PCR
(RT-qPCR) analysis also showed a correlation between the expression of pmrC and polymyxin B resistance.
Characterization of lipid A species from the mutant strains, by thin-layer chromatography and mass spec-
trometry, indicated that the addition of phosphoethanolamine to lipid A correlated with resistance. This
addition is performed in Salmonella enterica serovar Typhimurium by the product of the pmrC gene, which is
a homolog of the pmrC gene from Acinetobacter. Knockout of this gene in the mutant R2 [pmrB(T235I)] reversed
resistance as well as phosphoethanolamine modification of lipid A. These results demonstrate that specific
alterations in the sequence of the pmrCAB operon are responsible for resistance to polymyxins in A. baumannii.
Acinetobacter baumannii has emerged worldwide as an im-
portant nosocomial and opportunistic pathogen, particularly in
intensive care units (25). It has been implicated in ventilator-
associated pneumonia, bacteremia, wound infections, and sec-
ondary meningitis. Its natural resistance to desiccation, disin-
fectants, and antibiotics plays a key role in environmental
survival (39) and subsequently in outbreaks in health care
settings (25).
Treatment of these infections is often difficult, as clinical
isolates of A. baumannii are generally resistant to multiple
antibiotics (25). Carbapenems have remained the first-choice
option for serious infections caused by multidrug-resistant
(MDR) A. baumannii (5). However, the ability of this organism
to develop resistance has led to the emergence of extremely
drug-resistant (XDR) isolates displaying susceptibility only to
the polymyxins (8). Reduced susceptibility to tigecycline, the
first glycylcycline, in A. baumannii isolates has also been re-
ported (25).
As a result, polymyxins are being prescribed as the last
remaining therapeutic option (3, 18). It has been demonstrated
in a prospective study that intravenous colistin is safe and
effective (7), and there are lesser issues with polymyxin toxicity
than expected based on early experiences (18). Nevertheless,
the intensive use and the lack of an optimal dosing creates a
potential for colistin resistance (12, 17, 21, 31), and indeed,
some cases have already been reported (3, 16, 26, 34), includ-
ing a nosocomial outbreak of colistin-resistant A. baumannii
(37).
The mode of action of polycationic polymyxins involves the
initial interaction with polyanionic lipopolysaccharide (LPS)
found within the outer membrane, displacing divalent cations
that normally cross bridge adjacent LPS molecules required for
membrane stabilization (10). The resultant localized disrup-
tion of the outer membrane enables self-promoted uptake of
polycationic peptides across the outer membrane. In Salmo-
nella enterica serovar Typhimurium, Escherichia coli, and Pseu-
domonas aeruginosa, resistance can occur through modification
of the lipid anchor of LPS known as lipid A (2, 4, 9, 11, 13, 32).
For example, the addition of the cationic sugar L-4-amino-
arabinose to the lipid A phosphate groups of LPS alters the
dependency on divalent cation cross bridging for stabilization
of the outer membrane and consequently blocking self-pro-
moted uptake (9). This process is regulated by two-component
regulatory systems, including PhoPQ, PmrAB, and ParRS,
which respond to signals such as antimicrobial peptides, low
pH, and low Mg2 (2, 4, 9). Other lipid A modifications,
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including alteration of the number of acyl chains and addition
of phosphoethanolamine, can also occur (13, 32). Colistin re-
sistance in P. aeruginosa has been shown to occur in both cystic
fibrosis and other patients, and in the latter, the involvement of
the PhoPQ and PmrAB two-component regulatory systems has
been described (29).
Recently, two papers addressed the mechanism of colistin
resistance in A. baumannii (1, 22). Adams et al. (1) identified
a homolog of the pmrCAB operon in A. baumannii and dem-
onstrated that resistant mutants trained by growth on 1 g/ml
of colistin contained mutations in the pmrB gene with one
mutant having an additional pmrA mutation. However, this
study was somewhat limited by the fact that no genetic com-
plementation studies were performed to link these changes to
resistance, and indeed, MAC103, a revertant mutant isolated
by multiple passages on colistin-free medium, had the same
mutations as the original mutant, MAC101, despite a wild-type
(WT) MIC. Subsequently, Moffatt et al. (22) indicated that the
basis for polymyxin resistance in A. baumannii was mutations
in the first 3 genes of the lipid A biosynthesis pathway, namely,
lpxACD, and that this led to complete loss of LPS production
and supersusceptibility to other antibiotics.
Here, we utilized genetic methods, including knockouts of
pmrB and complementation of spontaneous and clinical resis-
tant mutants, to define the critical role of the pmrCAB system
in A. baumannii polymyxin resistance. Furthermore, we pro-
vide evidence that certain strains have lipid A modifications
that occur in a fashion consistent with a blockage of self-
promoted uptake of polymyxin across the outer membrane.
MATERIALS AND METHODS
Bacterial strains, plasmids, growth conditions, and antimicrobial agents. The
bacterial strains and plasmids used in this study are described in Table 1. A
collection of 10 polymyxin B-resistant A. baumannii clinical isolates from 5
different countries (isolated from 2001 to 2008 through the SENTRY surveil-
lance system or the University of Seville) was also included; susceptibility to a
variety of antibiotics and epidemiological data are shown in Table 2 and, overall,
suggested that these strains were independent isolates. All clinical isolates were
identified at the species level by amplified ribosomal rRNA gene restriction
TABLE 1. Strains, plasmids, and primers used to make the deletion mutants
Strain, plasmid, or primer Genotype, relevant phenotype,a or sequence Source or reference
A. baumannii strains
ATCC 17978 WT ATCC
R2, R3, R5, R6, R7, and R9 Polymyxin-resistant mutants spontaneously derived on gradient plates
from ATCC 17978
This study (Table 3)
E. coli strains
TOPO10 F mcrA D(mrr-hsdRMS-mcrBC) 80lacZ M15 D lacX74 recA1 araD
139 D (ara-leu)7697 galU galK rpsL (strR) endA1 nupG
Invitrogen
DH5 Invitrogen
W3110 Wild type; F  E. coli Genetic Stock
Center (Yale)
WD101 W3110 constitutive pmrA mutant (polymyxin resistant) 13
Plasmids
pCR-Blunt II-TOPO PCR cloning vector; Kmr Invitrogen
pUCK4 Source of Kmr kanamycin cassette gene Pharmacia
pEX18 Amp Suicide plasmid; Ampr; sacB 14
pWH1266 E. coli-Acinetobacter shuttle plasmid; Ampr CBr Tetr 15
pABN pWH1266 harboring pmrAB from the WT; CBr This study
pAB25 pWH1266 harboring pmrAB from R2; CBr This study
pAB10 pWH1266 harboring pmrAB from R5; CBr This study
Primers
AB pmrA NF CAGCAGTTTCTGTGCCATGT This study
KanPmrA NR TGAGACACAACGTGGCTTTCCCATCCATCATAGGCAATCC This study
KanPmrA CF ATTACGCTGACTTGACGGGAACCGTTTGGGGCAATCATA This study
AB pmrA CR TTTTGCATAGCCAAGTTGACC This study
nest-A-F CGGGTATGCCACGTGTAGAT This study
nest-A-R AATGCAGTCACAGGTGTTCG This study
AB pmrB NF GGTCATCAACCTCAACTGG This study
KanPmrB NR TGAGACACAACGTGGCTTTCGGGTGCTCAGCTGTTCTTTC This study
KanPmrB CF ATTACGCTGACTTGACGGGATTTACATGAAACAAGAGCGTGA This study
AB pmrB CR TTAAAGCGACCATTGGCATT This study
nestB-F GGTGGAATGGGTCAATAACG This study
nestB-R GAGTTCCGTGGTGCAGACTT This study
C0F TGATAAATTACGTGCGACTGC This study
KC1R1 TGAGACACAACGTGGCTTTCTTCAGCATCGTGAGTGACTACA This study
KC2F2 ATTACGCTGACTTGACGGGAGTGCCCATGTAAACTAAAGCG This study
YnewR TTGCCAATGCTAAAAGCTGA This study
C1F GCGTATTCGCCATGCTTATT This study
C2R GCTTCACGAACCCTCTCTTG This study
a Antibiotic resistance phenotypes: Kmr, kanamycin resistant, Ampr, ampicillin resistant for E. coli; CBr, carbenicillin resistant for A. baumannii; Tetr, tetracycline
resistant.
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analysis (ARDRA) (38). Cultures were routinely grown in Luria-Bertani (LB)
broth or cation-adjusted Mu¨ller-Hinton (CAMH) broth (BBL-Becton Dickin-
son). The antibiotics and concentrations used for selection in A. baumannii were
as follows: carbenicillin, 750 g/ml, and kanamycin, 50 g/ml. The antibiotics and
concentrations used for selection in E. coli were as follows: ampicillin, 100 g/ml,
and kanamycin, 50 g/ml. All antibiotics were purchased from Sigma. Polymyxin
B and colistin MICs were measured by the broth microdilution method according
to the Clinical and Laboratory Standards Institute (CLSI), using CAMH broth.
P. aeruginosa ATCC 27853 was included as a quality control strain. An MIC
breakpoint of4 g/ml was used to define resistance to polymyxin B and colistin
in clinical isolates of A. baumannii according to CLSI M100-S20 (2010).
In vitro generation of polymyxin B-resistant mutants. Late-log-phase WT LB
cultures were plated on gradient (4 to 50 g/ml) polymyxin B-LB agar plates and
then incubated at room temperature for 72 to 96 h (23). Colonies were confirmed
by six serial passages on polymyxin (4 g/ml) LB plates and subsequently by six
serial passages on drug-free LB plates, resulting in a polymyxin B resistance
phenotype.
Gene knockouts by homologous recombination. Splicing PCR was performed
as described previously (24), with slight modifications, to generate recombinant
DNA fragments consisting of a kanamycin cassette (obtained by PCR from
pUCK4 plasmid; Pharmacia) flanked by 1-kb chromosomal regions upstream
and downstream of the gene to be deleted. Forward and reverse primers for this
study (Table 1) were designed from the ATCC 17978 genome sequence (30)
using Primer3 (28). Phusion DNA polymerase (Fynnzimes, Finland) was used as
a high-fidelity DNA polymerase. The final PCR constructs were cloned into the
TOPO blunt-ended vector and excised using KpnI and PstI restriction enzymes,
and the excised fragment was cloned into the cognate sites of the pEX18Amp
plasmid (a gene replacement suicide vector for Acinetobacter spp.) (14). The
recombinant knockout plasmids were introduced into parental strains by elec-
troporation, and transformants were selected for kanamycin resistance and car-
benicillin susceptibility, resulting from a double crossover recombination event.
The final structure of cloned and knockout genes in all replacement vectors and
knockout mutant strains, including the flanking regions, was confirmed by PCR
analysis and sequencing. For generation of knockout A. baumannii clinical iso-
lates, strains C8 and C14 were selected because their antibiotic profile was
suitable for enabling mutant selection.
Sequencing of pmrCAB in clinical isolates and WT-derived mutant strains.
Genomic DNA was isolated using a DNeasy blood and tissue kit (Qiagen, Inc.,
Canada) according to the manufacturer’s instructions. The pmrCAB genes were
amplified and sequenced. A set of PCR primers was designed to encompass the
entire operon and flanking regions (4.5 kb). Sequencing of both strands was
performed using Applied Biosystems BigDye Terminator version 3.1 chemistry
and run on an Applied Biosystems Prism 377 automated sequencer.
Construction of the pmrAB-complemented strains. To complement the dis-
rupted pmrB mutants, the contiguous pmrAB genes were cloned together with
252 bp of upstream DNA and 89 bp of downstream DNA. Fragments were PCR
amplified from ATCC 17978, and mutants R2 and R5, cloned into the TOPO
vector, were excised using BamHI and subsequently cloned into the cognate sites
of the expression vector pWH1266 (15), resulting in plasmids pABN, pAB25, and
pAB10, respectively.
RT-qPCR. The A. baumannii WT strain ATCC 17978 or derivatives and
clinical isolates were grown to the mid-logarithmic phase of growth in CAMH
broth, and cells were harvested at an optical density at 600 nm (OD600) between
0.5 and 0.6. Total RNA was extracted using a Qiagen Easy minikit and RNeasy
minicolumns. DNase treatment of RNA samples, cDNA synthesis, and reverse
transcription-quantitative PCR (RT-qPCR) were carried out as described pre-
viously (4). cDNA was diluted 1:100, and 2.5 l was used as a template for each
reaction, using 1 SYBR green PCR master mix (Applied Biosystems, Foster
City, CA) and an ABI Prism 7000 instrument (Applied Biosystems). Internal
forward and reverse primers for each gene were designed using PrimerExpress
(Applied Biosystems). Experiments were repeated with three independent cul-
tures, each tested in duplicate. Comparison to the 16S ribosomal gene allowed
calculation of the fold change by the threshold cycle (CT) method (19).
TLC analysis of lipid A species from 32Pi-labeled cells. Strains of E. coli and
A. baumannii were labeled using 2.5 Ci/ml 32Pi at a starting OD600 of0.05 and
harvested at an OD600 of 1.0. Cultures were grown at 37°C in LB broth.
32P-labeled lipid A species were isolated and separated by thin-layer chroma-
tography (TLC) using published protocols (13). TLC plates were exposed over-
night to a phosphorimager screen and visualized using a Bio-Rad personal
molecular imager (PMI) equipped with Quantity One software.
Analysis of lipid A by mass spectrometry. Bacterial strains were grown at 37°C
in LB broth until each culture reached an OD600 of 1.0. Lipid A was purified
as described previously and analyzed by matrix-assisted laser desorption ioniza-
tion–time of flight (MALDI-TOF) mass spectrometry in the negative-ion-reflec-
tron mode (11). The matrix used was a saturated solution of 6-aza-2-thiothymine
in 50% acetonitrile and 5% tribasic ammonium citrate (20:1, vol/vol). A 0.6-l
volume of matrix solution was deposited on the sample plate, followed by 0.4 l
of sample dissolved in chloroform-methanol (4:1, vol/vol) (11).
Nucleotide sequence accession numbers. The nucleotide sequences of
pmrCAB from polymyxin B-resistant spontaneous laboratory WT-derived mu-
tants and clinical isolates of A. baumannii have been submitted to the GenBank
nucleotide sequence databases under the accession numbers JF766938 to
JF766953.
RESULTS
Polymyxin-resistant spontaneous mutants. To isolate poly-
myxin-resistant mutants of the wild-type A. baumannii strain
ATCC 17978, the organism was plated onto polymyxin B gra-
TABLE 2. Sources of specimens, origins, and antibiotic profiles for 10 polymyxin B-resistant clinical isolates of A. baumannii
Isolate Clinical sourcea Origin
MIC (g/ml)
COLb PXBb IMPc MEMc FEPc CAZc P/Tc A/Sc AMKc GENc TOBc CIPc T/Sc DOXc MINc TIGc
C2 BAL (XDR)d Spain 64 16 	8 	8 	16 	16 	64 	16 	32 	8 16 	2 	2 	8 	8 1
C4 Blood (XDR)d U.S. 32 64 	8 	8 	16 	16 	64 	16 	32 	8 	16 	4 	2 	8 	8 0.5
C5 Pleural fluid U.S. 16 32 8 	8 16 	16 	64 8 8 	8 1 	4 	2 4 2 2
C8 Blood U.S. 32 16 4 8 8 	16 64 4 4 2 0.5 	4 1 2 2 2
C11 BAL Israel 8 16 0.5 4 	16 	16 64 8 	32 	8 	16 	4 	2 1 1 1
C12 Blood (MDR)d U.S. 16 16 	8 	8 16 	16 	64 32 16 	8 	16 	4 	2 2 2 1
C13 BAL U.S. 16 16 4 8 	16 	16 	64 	16 8 	8 16 	4 	2 2 1 ND
C14 Wound Brazil 32 8 0.5 1 8 	16 	64 8 2 2 0.5 	4 0.5 0.25 0.25 ND
C15 Blood France 128 64 2 1 8 	16 0.5 4 32 	8 	16 	4 0.5 	8 4 ND
C87 VCT (MDR)d Spain 64 16 	8 	8 	16 	16 	64 
8 	32 	8 	16 	4 	2 ND 0.5 0.5
a BAL, bronchoalveolar lavage; VCT, ventricular catheter tip.
b Colistin (COL) and polymyxin B (PXB) MICs were determined by the broth microdilution method according to the Clinical and Laboratory Standards Institute
(CLSI; 2009).
c MICs were determined by the broth microdilution M07-A8 method (CLSI; 2009) using commercially prepared and validated panels (TREK Diagnostic Systems,
OH) in CAMH broth to the following antibiotics: IMP, imipenem; MER, meropenem; FEP, cefepime; CAZ, ceftazidime; P/T, piperacillin-tazobactam; A/S,
ampicillin-sulbactam; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; T/S, trimethoprim-sulfamethoxazole; DOX, doxycycline; MIN,
minocycline; and TIG, tigecycline. ND, not done.
d The clinical isolates were classified according to their susceptibility to the antimicrobials listed above (excluding colistin/polymyxin B and tigecycline) as follows:
multidrug resistant (MDR), resistant to at least 3 antimicrobial families (including carbapenems) and displaying variable susceptibility to the remaining agents, and
extremely drug resistant (XDR), resistant to all the antibiotics listed (8). Susceptibility interpretations were performed according to the CLSI (2010) criteria, when
available. Due to the lack of CLSI breakpoints for tigecycline in Acinetobacter, no susceptibility could be inferred. Antibiotic profiles were categorized as MDR or XDR.
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dient plates. After 72 to 96 h, nine colonies grew at concen-
trations that inhibited the parent strain. After 6 serial passages,
only six, R2, R3, R5, R6, R7, and R9, demonstrated stable
resistance, forming colonies that were able to grow on poly-
myxin B plates; all of these continued to display polymyxin
resistance after 6 serial passages on drug-free plates. The re-
sulting polymyxin B MICs were between 2 and 8 g/ml, com-
pared to the parental MIC of 0.5 g/ml (Table 3). No signifi-
cant changes were observed in susceptibility to any other tested
antibiotic, including imipenem, meropenem, cefepime, cef-
tazidime, piperacillin-tazobactam, ampicillin-sulbactam, ami-
kacin, gentamicin, tobramycin, ciprofloxacin, trimethoprim-
sulfamethoxazole, doxycycline, minocycline, tigecycline, or
different cationic peptides (indolicidin, LL-37, hLF1-11, HH2,
E6, Bac2A, and MX-226).
Sequence analysis of the polymyxin resistance operon
pmrCAB in mutants. Homology searches revealed an operon
(loci A1S_2752 to -2750) with homology to the pmrCAB
operon of Salmonella with the predicted genes having moder-
ate 42, 45, and 28% identity (60, 61, and 47% similarity) to the
corresponding genes of Salmonella, STM4293 (pmrC), -4291
(pmrA), and -4290 (pmrB), respectively. The genes in Salmo-
nella encode a lipid A phosphoethanolamine transferase
(pmrC), response regulator (pmrA), and histidine kinase
(pmrB), with the last two being components of a two-compo-
nent signal transduction system. No other two-component reg-
ulators with homology to that of known polymyxin resistance
regulatory genes were observed in A. baumannii, which was in
good agreement with the conclusions of Adams et al. (1). We
were unable to identify strong homologs of any other poly-
myxin resistance genes of Pseudomonas or Salmonella, includ-
ing the arnBCADTEF (lipid A arabinosaminylation) operon,
pagP, pagL, or lpxR genes. The pmrCAB operons from the
above-described polymyxin-resistant mutants of strain ATCC
17978 were sequenced to reveal potential differences (Table 3).
No changes in the pmrC gene were observed in any mutant.
One mutant, R5, had a mutation in the predicted receiver
domain of the response regulator gene pmrA, while the re-
maining 5 mutants had mutations in the histidine kinase gene
pmrB in either the predicted histidine kinase domain (R2 and
R9 with mutations in residues 235 and 231, respectively) or
residue 315 (R3 and R7) or two separate mutations, one of
which was in the histidine kinase domain (R6).
Knockout mutants exhibit different MICs for polymyxin B.
To confirm that the described mutations were responsible for
resistance, pmrB was knocked out by insertion of a kanamycin
cassette into the pmrB gene of 2 selected mutants, R2 and R5
(Table 4). In each case, MICs for polymyxin B were decreased
by 8- to 16-fold. In contrast, knockout of pmrB (or pmrA or
pmrC; data not shown) in the wild-type background caused no
significant change (2-fold) in polymyxin B MICs, indicating
that this operon contributes modestly at most to intrinsic re-
sistance. Knockout of pmrC, the first gene in the operon led to
complete suppression of polymyxin resistance in the mutant
R2::pmrC (MIC  0.25 g/ml), although, despite multiple
attempts, we were unable to perform the same knockout in the
TABLE 3. Amino acid changes or mutations in the pmrCAB polymyxin B-resistant WT-derived strains (compared to their parental WT strain
ATCC 17978) and pmrCAB variants of polymyxin B-resistant clinical isolates (compared to a consensus sequence)a
Strain PXB
b MIC
(g/ml)
Amino acid change(s) inc:
pmrC (549 aa) pmrA (224 aa) pmrB (444 aa)
aa 1–236 Sulfatase(aa 237–532)
Rec
(aa 5–116) aa 117–131 aa 1–215
HisK
(aa 216–276) aa 277–330
HATPaseC
(aa 331–419)
WT 0.5
R9 2 R231L
R3 4 G315D
R5 4 M12I
R6 4 R263P Q277H
R7 4 G315D
R2 8 T235I
C14 8 T7I, A211V 160
C2 16 D64V, L208F
C8 16 L208F
C11 16 H499R* 32–35 P360Q*
C13 16 P170Q
C12 16 N256I
C87 16 F90L S119T P233S P360Q*
C5 32 R263C P377L
C4 64 A226V
C15 64 A80V, P170L
a Sequences were compared to a consensus sequence made by alignment of the pmrCAB operons from the genome sequences of the following strains: ATCC 17978
(Yale University); AYE (Genoscope, France); ACICU (National Research Centre, Italy); AB0057, AB307-0294, and AB900 (Case Western Reserve University);
1656-2 (Kyungpook National University/GenoTech Corporate, South Korea), and TCDC-AB0715 (Taiwan Center for Disease Control, Taiwan). Accordingly, the
identified single nucleotide polymorphisms (SNPs; naturally variant between the sequenced isolates) pmrC(F166L), pmrC(A370S), pmrC(K531T), and pmrB(A444V)
occurred in each of the clinical isolates C2, C4, C5, C8, C12, C13, and C15 but not in C11, C14, or C87. In addition, the SNP pmrC(H499R) (marked with an asterisk)
was found only in clinical isolate C11. The SNP pmrB(P360Q) (marked with an asterisk) occurred in clinical isolates C11 and C87 but none of the other strains. aa,
amino acids.
b Polymyxin B (PXB) MICs were assessed by the broth microdilution method according to the CLSI.
c The predicted domains according to the NCBI domain predictor (www.ncbi.nlm.nhi.gov/protein) are indicated as follows: sulfatase, sulfatase domain; Rec, signal
receiver domain; HisK, histidine kinase (dimerization/phosphoacceptor) domain; and HATPaseC, histidine-kinase-like ATPase. Only domains or regions displaying
mutations or variants are shown. The amino acid (aa) positions corresponding to these domains are displayed in brackets.
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mutant R5. Knockout mutants exhibited no significant changes
in susceptibility to other antibiotics (data not shown).
Clinical isolates. Ten clinical polymyxin B-resistant isolates
were obtained from the SENTRY surveillance program and
University of Seville. Each was resistant to multiple antibiotics
(Table 2), with 4 strains being designated multidrug resistant
(C12 and C87) or extremely drug resistant (C2 and C4). Poly-
myxin MICs varied from 8 to 64 g/ml, and colistin MICs
ranged from 8 to 128 g/ml. To define the potential presence
of variants leading to resistance, the entire pmrCAB operon
from each isolate was sequenced. Considering these were in-
dependent clinical isolates from a variety of clinical situations
and countries, the gene sequences were fairly conserved. Re-
garding pmrC, two isolates displayed variants in a region of
unknown function (T7I and A211V in C14 and F90L in C87).
All clinical isolates had different variants of pmrB, with 4 of
them having alterations in the kinase domain. Excluding the
potential single nucleotide polymorphisms (SNPs) identified in
the pmrB gene (Table 3), we found that three isolates (C2, C5,
and C15) had two variants while C11 and C14 had small in-
frame deletions. One strain, C87, had an additional variant of
pmrA, although not within the receiver domain.
To test the involvement of the two-component system
PmrAB in the resistant phenotype of these strains, the pmrB
gene was knocked out by insertion of a kanamycin cassette into
the pmrB genes of 2 clinical isolates, C8 and C14 (Table 4).
This deletion caused 64-fold and 4-fold increases in suscepti-
bility to polymyxin B, respectively.
Complementation of pmrAB mutations. To further demon-
strate that pmrB played a role in the polymyxin-resistant phe-
notype, we attempted to complement the susceptibility pheno-
type created through the knockout of pmrB in the mutant R2
(Table 5). As expected, the cloned pmrAB genes from the
wild-type strain did not increase the level of polymyxin resis-
tance but the pmrAB genes from the R2 mutant [carrying the
pmrB(T235I) mutation] were able to reconstitute resistance.
Similarly, the pmrAB genes from the mutant R5 [carrying the
pmrA(M12I) mutation] were able to reconstitute resistance,
indicating that alterations in either component of this regula-
tory system, PmrA or PmrB, can lead to resistance.
Analysis of pmrCAB transcription in different strains. We
hypothesized that the polymyxin-resistant phenotype would be
associated with increased expression of the pmrCAB operon, in
particular that of pmrC, which encodes the protein that adds
phosphoethanolamine to lipid A. For this reason, we studied
the transcription levels of this operon in different strains com-
pared to the level for ATCC 17978. These strains included the
resistant mutants and clinical isolates R2, R5, C8, and C14, the
pmrB deletion mutants corresponding to R2, R5, C8 and C14,
and the complemented R2 pmrB deletion mutant carrying the
pmrAB genes from the wild type or from the R2-resistant strain
(Table 6).
In general, we observed a direct correlation between the
greater expression of the pmrC gene and resistance to poly-
myxin B. Thus, the five resistant strains tested, which included
the clinical isolates C8 and C14 together with the laboratory
isolated mutants R2 and R5, showed increases in the transcrip-
tion of pmrC from 26- to 292-fold, compared to the level for
our laboratory wild-type strain ATCC 17978.
Upon deletion of pmrB, the spontaneous resistant mutants
R2 and R5 recovered transcription levels and polymyxin B
MICs that were comparable to those of their parent strain. The
results of the analysis of the pmrB deletion mutants derived
from the clinical isolates C8 and C14 were slightly more com-
plex. Thus, deletion of pmrB in strain C8 resulted in a loss of
the resistance phenotype and a significant 43-fold decrease in
the transcription of pmrC, although the expression of pmrC
was still 6-fold higher than that of ATCC 17978. For isolate
C14, for which the deletion mutant demonstrated only a partial
restoration of polymyxin B susceptibility, RT-qPCR analysis
revealed that this mutant did not completely lose the expres-
sion of the deleted gene pmrB. This is consistent with the
interpretation that there might be a more complex regulatory
mechanism or a second copy of the operon in this strain.
TABLE 4. Polymyxin B MIC changes in pmrB::Km
knockout mutants
Parental strain
Polymyxin B MIC (g/ml)
Parent pmrB::Km insertion mutant
WT 0.5 0.25
R2 8 0.5
R5 4 0.5
C8 16 0.25
C14 8 2
TABLE 5. Polymyxin B susceptibility and lipid A profile lane in
mutant R2 and complemented A. baumannii strains
Inserted mutation Complementinggene
Polymyxin
B MIC
(g/ml)
Lipid A profile
(lane in Fig. 1)
None (mutant R2) None 8 2
pmrB::Km None 0.5 3
pmrB::Km pWH1266 (empty
vector)
0.5
pmrB::Km pmrABWT 0.25
pmrB::Km pmrABR2 4 4
pmrB::Km pmrABR5 4 5
TABLE 6. RT-qPCR analysis of the expression of pmrCAB in
different strains compared to the level for the laboratory
wild-type strain ATCC 17978a
Strain
Mean fold change  SD
pmrC pmrA pmrB
R2 224.8  140.6 51.7  32.7 30.5  18.5
R2 pmrB::Km 1.43  0.09 1.3  0.4 
R2 pmrB::Km 
pmrABWT
1.0  0.3 49.5  8.1 189.9  17.0
R2 pmrB::Km 
pmrABR2
567.0  137.0 58.8  6.2 77.0  9.2
R5 165.2  27.6 18.5  0.4 10.6  0.3
R5 pmrB::Km 2.0  1.2 0.9  0.2 
C8 292.1  18.3 4.3  0.05 2.7  0.3
C8 pmrB::Km 6.8  0.6 1.7  0.08 
C14 26.5  3.3 4.1  0.7 3.2  0.5
C14 pmrB::Km 16.2  1.8 2.9  1.7 0.9  0.1
a The values represent three independent samples, with each assessment being
repeated in duplicate. , no expression of pmrB could be detected in these
strains.
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Finally, we also evaluated the expression of the genes in the
pmrCAB operon in two complemented pmrB deletion mutants
derived from strain R2, carrying in trans copies of the pmrAB
genes from either the parent ATCC 17978 (pmrABWT) or the
R2-resistant mutant (pmrABR2). In both cases, a high level of
overexpression of pmrA and pmrB can be observed. However,
only the strain carrying the mutant copy of pmrB (pmrABR2)
leads to an overexpression of pmrC and to polymyxin B resis-
tance. In contrast, overexpression of the wild-type copy of
these genes does not result in increased expression of the
chromosomally located gene pmrC, nor does it confer in-
creased resistance.
Polymyxin-resistant strain mutants have a modified lipid A
profile. To examine whether modification of lipid A played a
role in conferring polymyxin resistance in A. baumannii, cul-
tures were radiolabeled with 32Pi and the purified lipid A
species was isolated and separated using TLC (Fig. 1). As
controls, lipid A of a polymyxin-resistant E. coli K-12 strain
(WD101) and its polymyxin-sensitive parent strain (W3110)
were included in the analysis. PmrA is constitutively active in
WD101, resulting in modification of lipid A phosphate groups
with phosphoethanolamine and L-4-aminoarabinose (13, 32).
E. coli K-12 produced two hexa-acylated lipid A species, 1,4-
bis-phosphate lipid A and 1-diphosphate lipid A, respectively
(Fig. 1, lane 9). As previously reported for WD101, modifica-
tion of both phosphate groups with phosphoethanolamine and
L-4-aminoarabinose resulted in slower-migrating species (lane
10) (13, 32).
Wild-type A. baumannii ATCC 17978 produced lipid A spe-
cies migrating with Rf values of 0.63 to 0.70 (Fig. 1, lane 1),
whereas the lipid A species from strain R2 were more hydro-
philic in nature, with Rf values of 0.17 to 0.29 (lane 2), sug-
gesting modification of lipid A. Deletion of pmrB in strain R2
resulted in the loss of this modification in lipid A migration
(lane 3), while the complementation with the pmrAB genes
from R2 (plasmid pAB25) restored lipid A modification (lane
4). A similar result was obtained using plasmid pAB10 express-
ing pmrAB genes from the polymyxin-resistant strain R5 (lane
5). An insertion in the pmrC gene, encoding a putative A.
baumannii phosphoethanolamine transferase, also resulted in
the loss of lipid A modification. Finally, clinical isolate C8 had
a modified lipid A profile (lane 7), and deletion of pmrB in this
background resulted in loss of lipid A modification. Taken
together, these results demonstrate that polymyxin-resistant
strains of A. baumannii displayed modified forms of lipid A on
their surface and that the appearance of these modified forms
was consistent with the polymyxin B MICs of the respective
strains.
Purified lipid A from A. baumannii was also subjected to
analysis by MALDI-TOF mass spectrometry in the negative-
ion mode (Fig. 2). The wild-type spectrum showed a predom-
inant peak at an m/z of 1,910.9, consistent with a [M-H] ion
of a hepta-acylated, bis-phosphorylated lipid A species (pre-
dicted [M-H] at an m/z of 1,910.29). A second predominant
peak at an m/z of 1,728.8 was consistent with a [M-H] ion of
a hexa-acylated, bis-phosphorylated lipid A species (predicted
FIG. 1. Analysis of 32P-labeled lipid A species isolated from A. baumannii and E. coli strains. 32P-labeled lipid A species isolated from the
indicated bacterial strains were separated by TLC and visualized by phosphorimaging analysis. As shown previously, polymyxin-resistant E. coli
(WD101) produced lipid A species modified with L-4-aminoarabinose and phosphoethanolamine, including doubly modified lipid A species (13,
32). Polymyxin B-resistant strains of A. baumannii produced slower migrating, more hydrophilic lipid A species (Rf values of 0.17 to 0.29),
compared to the lipid A of polymyxin B-sensitive strains (Rf values of 0.63 to 0.70). The major
32P-labeled lipid A species are indicated with arrows.
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[M-H] at an m/z of 1,728.12). The predicted lipid A structures
are shown in Fig. 2A and are in agreement with a previously
reported mass spectrometry analysis of wild-type A. baumannii
lipid A (20). As expected, mass spectrometry analysis of the
polymyxin-resistant R2 variant (Fig. 2B) revealed modified
lipid A structures. The predominant peak at an m/z of 2,033.7
was consistent with the [M-H] ion of hepta-acylated, bis-
phosphorylated lipid A modified with a phosphoethanolamine
residue (predicted [M-H] at an m/z of 2,033.30). A minor
peak at an m/z of 2,156.8 was also present and was consistent
with a lipid A species bearing two phosphoethanolamine res-
idues (predicted [M-H] at an m/z of 2,156.30). The predicted
lipid A structures of strain R2 are shown in Fig. 2B. Similar
spectra were obtained upon analysis of lipid A isolated from
strain C8 (data not shown). Additional peaks of lower intensity
are explained in the figure legend.
DISCUSSION
As polymyxin is becoming a drug of last hope for the often
multidrug-resistant species A. baumannii, understanding poly-
myxin resistance is of great interest. Here, we have confirmed,
using genetic means, the involvement of an operon that was
suggested by Adams et al. (1) to control polymyxin resistance
in A. baumannii and that demonstrates moderate homology to
the pmrCAB operon of Salmonella Typhimurium. Our results
indicate that the two-component regulator PmrAB regulates
polymyxin resistance. Spontaneous mutants isolated from the
FIG. 2. Mass spectrometry of lipid A isolated from wild-type and polymyxin-resistant A. baumannii. Lipid A was isolated from wild-type strain
ATCC 17978 and wild-type-derived R2, followed by MALDI-TOF mass spectrometry in the negative-ion mode. (A) Wild-type 17978 produced
peaks at m/z values of 1,910.9 and 1,728.8, corresponding to bis-phosphorylated hepta- and hexa-acylated lipid A species, respectively. The minor
peak at an m/z of 1,933.9 represents a sodium adduct of the parent ion. The peak at an m/z of 1,882.9 arises from lipid A with an acyl chain reduced
by 2 carbons in length compared to that of the major ion. (B) Strain 17978 R2 produced peaks at m/z values of 2,033.7 and 2,156.8, corresponding
to bis-phosphorylated hepta-acylated lipid A decorated with one and two phosphoethanolamine groups, respectively. Minor peaks at m/z values
of 2,055.7 and 2,077.7 represent sodium adducts of the major parent ion. The minor peak at an m/z of 2,005.7 arises from lipid A with an acyl chain
reduced by 2 carbons in length compared to that of the major ion. The peak at an m/z of 1,851.7 is bis-phosphorylated, hexa-acylated lipid A with
a single phosphoethanolamine residue.
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wild-type A. baumannii strain ATCC 17978 had 4- to 16-fold
changes in polymyxin B MIC and mutations in either pmrB (4
different mutations in 5 strains) or pmrA (1 mutation isolated).
These results are in part consistent with those found by Adams
et al. (1) and also in polymyxin-resistant E. coli and Salmonella
Typhimurium, where polymyxin resistance mutations were
found to be located within the receiver domain of the PmrA
regulator (6, 27, 33). In addition, mutations have been identi-
fied in pmrB in polymyxin-resistant P. aeruginosa (23).
The effects of these mutations on polymyxin resistance in 2
selected mutants could be eliminated by knocking out the
pmrB gene by insertion of a kanamycin cassette and then re-
stored by complementation with the mutated pmrAB genes
from two spontaneous mutants but not with the wild-type
genes. Transcriptional analysis showed that the resistant mu-
tants had an overexpression of the pmrCAB operon that was
abrogated when pmrB was deleted. Adams et al. (1) had al-
ready reported that the level of pmrA expression was higher in
colistin-resistant mutants. Furthermore, our data indicate that
pmrAB overexpression is not sufficient to result in increased
polymyxin resistance, unless there is also an overexpression of
pmrC, which encodes the lipid A modification enzyme phos-
phoethanolamine transferase. These data indicate that the mu-
tations have a dominant effect (gain of function) on the activity
of the pmrCAB operon, leading to constitutive expression of
the regulon controlled by these genes. Interestingly, we also
tested these mutants and complemented strains for suscepti-
bility to 6 diverse antimicrobial peptides and demonstrated
minimal changes in susceptibility (2-fold; data not shown),
consistent with our data for Pseudomonas (4), indicating that
resistance to polymyxin and antimicrobial peptides is sepa-
rately determined in A. baumannii.
Results for clinical isolates taken from the SENTRY sur-
veillance program and the University of Seville were also con-
sistent with these data. Although these mutants were obtained
from 5 different countries, and had diverse other resistances,
they demonstrated moderate overall conservation of sequence
in the pmrAB and pmrC genes, but each of these had sequence
alterations in the pmrB gene as well as apparent SNPs (P360Q
and A444V). Only one of these strains had an additional
variant in the pmrA gene, although it was not located within
the receiver domain. Four common SNPs, pmrC(F166L),
pmrC(A370S), pmrC(K531T), and pmrB(A444V), which occur
in a subset of the sequenced A. baumannii strains, were also
found within the pmrC and pmrB genes in 7 clinical isolates,
C2, C4, C5, C8, C12, C13, and C15, but not C11, C14, or C87.
An apparent SNP, pmrC(H499R), was found only in isolate
C11. For the two clinical isolates investigated in greater detail,
C14 and C8, the knockout of pmrB caused a decrease in resis-
tance. However, this appeared to be only partial (4-fold) in the
case of C14, which might be explained, based on expression
analysis carried out with these strains, by additional regulatory
elements or the existence of a second copy of the pmrC gene.
The presence of additional copies of some of the genes in the
pmrCAB operon might also be a factor in some clinical strains,
as additional open reading frames (ORFs) are annotated as
lipid A phosphoethanolamine transferases in the genomes of
MDR clinical isolates such as strains 1656-2 and TCDC-
AB0715. However, further studies, including genome sequenc-
ing, would be necessary to establish the likelihood of any these
possibilities.
In other Gram-negative bacteria, two-component regulatory
systems control polymyxin resistance by altering the lipid A
species of LPS, consequently decreasing self-promoted uptake
of this polycationic antibiotic. These modifications can include
the addition of arabinosamine or phosphoethanolamine to the
phosphate residues of lipid A or the alteration in acylation to
change the charge or fluidity of the lipid A, respectively, and
consequently decrease self-promoted uptake across the outer
membrane. Here, it appeared that the pmrAB operon also
controlled lipid A modification, specifically, in the case of
strain ATCC 17978, the addition of phosphoethanolamine.
These data differ from the observations of Moffatt et al. (22),
who indicated that polymyxin resistance in A. baumannii is
associated with a loss of LPS. Our results clearly show that loss
of LPS is not the only mechanism of resistance to polymyxins
in this microorganism, as we clearly demonstrated the presence
of LPS/lipid A in the mutants studied, as well as the impor-
tance of modified LPS in these strains as a result of alterations
in PmrAB. Another difference from the Moffatt et al. study is
that we did not observe the 32- to 256-fold increase in suscep-
tibility to other classes of antibiotics. Furthermore, the obser-
vation of heteroresistance to polymyxin in A. baumannii is
entirely consistent with differential (epigenetic) regulation of
pmrAB, as observed for skipped well resistance in Pseudomo-
nas (29).
In Salmonella, the pmrC gene is involved in adding phos-
phoethanolamine to lipid A. Knockout of the pmrC gene in the
A. baumannii spontaneous mutant R2 led to increased suscep-
tibility to polymyxin B and reversed the modification in lipid A
profiles observed in thin-layer-chromatography analyses. How-
ever, the situation was not as clear for the two clinical isolates
investigated, C8 and C14, which could be related to additional
regulatory elements or the presence of additional copies of
pmrC or the pmrCAB operon, as suggested above. This could
also indicate that polymyxin resistance might be more compli-
cated in clinical isolates and that there might be other pmrAB-
dependent and/or -independent mechanisms in these isolates.
Overall, we have identified here an important mechanism of
resistance for the last-hope antibiotics polymyxins. Although
the sequenced A. baumannii strains lack homologs of the other
regulatory and effector mechanisms involved in polymyxin re-
sistance in other bacteria, which reduces the number of poten-
tial target genes that upon mutation lead to polymyxin resis-
tance in the laboratory or the clinic, this bacterium can become
resistant through a diversity of independent mutations in the
pmrCAB operon. Given that we found no obvious overlap in
resistance between polymyxin and cationic antimicrobial pep-
tides, it will be interesting to see if new modified polymyxin
derivatives demonstrate cross-resistance (35, 36), providing a
potential new avenue to therapeutic success.
ACKNOWLEDGMENTS
This work was supported by grants from the Canadian Cystic Fibro-
sis Foundation and the Canadian Institutes of Health Research.
R.E.W.H. holds a Canada Research Chair. L.A.A. was the recipient of
La Caixa Postgraduate Research Award (Barcelona, Spain). M.S.T.,
C.M.H., and J.V.H. are supported by National Institutes of Health
(NIH) grants AI064184 and AI76322.
3750 ARROYO ET AL. ANTIMICROB. AGENTS CHEMOTHER.
We are grateful to R. N. Jones and R. Mendes (JMI Labs) and J.
Aznar (University of Seville, Spain) for kindly providing antibiotic-
resistant isolates.
REFERENCES
1. Adams, M. D., et al. 2009. Resistance to colistin in Acinetobacter baumannii
associated with mutations in the PmrAB two-component system. Antimi-
crob. Agents Chemother. 53:3628–3634.
2. Bader, M. W., et al. 2005. Recognition of antimicrobial peptides by a bac-
terial sensor kinase. Cell 122:461–472.
3. Falagas, M. E., et al. 2005. Outcome of infections due to pandrug-resistant
(PDR) Gram-negative bacteria. BMC Infect. Dis. 5:24.
4. Fernandez, L., et al. 2010. Adaptive resistance to the “last hope” antibiotics
polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel
two-component regulatory system ParR-ParS. Antimicrob. Agents Che-
mother. 54:3372–3382.
5. Fishbain, J., and A. Y. Peleg. 2010. Treatment of Acinetobacter infections.
Clin. Infect. Dis. 51:79–84.
6. Froelich, J. M., K. Tran, and D. Wall. 2006. A pmrA constitutive mutant
sensitizes Escherichia coli to deoxycholic acid. J. Bacteriol. 188:1180–1183.
7. Garnacho-Montero, J., et al. 2003. Treatment of multidrug-resistant Acin-
etobacter baumannii ventilator-associated pneumonia (VAP) with intrave-
nous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect.
Dis. 36:1111–1118.
8. Giske, C. G., D. L. Monnet, O. Cars, and Y. Carmeli. 2008. Clinical and
economic impact of common multidrug-resistant gram-negative bacilli. An-
timicrob. Agents Chemother. 52:813–821.
9. Gooderham, W. J., and R. E. W. Hancock. 2009. Regulation of virulence and
antibiotic resistance by two-component regulatory systems in Pseudomonas
aeruginosa. FEMS Microbiol. Rev. 33:279–294.
10. Hancock, R. E. W., and D. S. Chapple. 1999. Peptide antibiotics. Antimicrob.
Agents Chemother. 43:1317–1323.
11. Hankins, J. V., and M. S. Trent. 2009. Secondary acylation of Vibrio chol-
erae lipopolysaccharide requires phosphorylation of KDO. J. Biol. Chem.
284:25804–25812.
12. Hawley, J. S., C. K. Murray, and J. H. Jorgensen. 2008. Colistin heterore-
sistance in Acinetobacter and its association with previous colistin therapy.
Antimicrob. Agents Chemother. 52:351–352.
13. Herrera, C. M., J. V. Hankins, and M. S. Trent. 2010. Activation of PmrA
inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to
antimicrobial peptides. Mol. Microbiol. 76:1444–1460.
14. Hoang, T. T., R. R. Karkhoff-Schweizer, A. J. Kutchma, and H. P. Schweizer.
1998. A broad-host-range Flp-FRT recombination system for site-specific
excision of chromosomally-located DNA sequences: application for isolation
of unmarked Pseudomonas aeruginosa mutants. Gene 212:77–86.
15. Hunger, M., R. Schmucker, V. Kishan, and W. Hillen. 1990. Analysis and
nucleotide sequence of an origin of DNA replication in Acinetobacter cal-
coaceticus and its use for Escherichia coli shuttle plasmids. Gene 87:45–51.
16. Ko, K. S., et al. 2007. High rates of resistance to colistin and polymyxin B in
subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob.
Chemother. 60:1163–1167.
17. Li, J., et al. 2006. Heteroresistance to colistin in multidrug-resistant Acin-
etobacter baumannii. Antimicrob. Agents Chemother. 50:2946–2950.
18. Li, J., et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant
Gram-negative bacterial infections. Lancet Infect. Dis. 6:589–601.
19. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression
data using real-time quantitative PCR and the 2CT method. Methods
25:402–408.
20. March, C., et al. 2010. Dissection of host cell signal transduction during
Acinetobacter baumannii-triggered inflammatory response. PLoS One
5:e10033.
21. Matthaiou, D. K., et al. 2008. Risk factors associated with the isolation of
colistin-resistant gram-negative bacteria: a matched case-control study. Crit.
Care Med. 36:807–811.
22. Moffatt, J. H., et al. 2010. Colistin resistance in Acinetobacter baumannii is
mediated by complete loss of lipopolysaccharide. Antimicrob. Agents Che-
mother. 54:4971–4977.
23. Moskowitz, S. M., R. K. Ernst, and S. I. Miller. 2004. PmrAB, a two-
component regulatory system of Pseudomonas aeruginosa that modulates
resistance to cationic antimicrobial peptides and addition of aminoarabinose
to lipid A. J. Bacteriol. 186:575–579.
24. Murphy, K. C., K. G. Campellone, and A. R. Poteete. 2000. PCR-mediated
gene replacement in Escherichia coli. Gene 246:321–330.
25. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter baumannii:
emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538–582.
26. Reis, A. O., D. A. Luz, M. C. Tognim, H. S. Sader, and A. C. Gales. 2003.
Polymyxin-resistant Acinetobacter spp. isolates on dry surfaces. Emerg. In-
fect. Dis. 9:1025–1027.
27. Roland, K. L., L. E. Martin, C. R. Esther, and J. K. Spitznagel. 1993.
Spontaneous pmrA mutants of Salmonella typhimurium LT2 define a new
two-component regulatory Salmonella typhimurium LT2 define a new two-
component regulatory system with a possible role in virulence. J. Bacteriol.
175:4154–4164.
28. Rozen, S., and H. J. Skaletsky. 2000. Primer3 on the WWW for general users
and for biologist programmers, p. 365–386. In S. Krawetz and S. Misener
(ed.), Bioinformatics methods and protocols: methods in molecular biology.
Humana Press, Totowa, NJ.
29. Schurek, K. N., et al. 2009. Involvement of pmrAB and phoPQ in polymyxin
B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of
Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4345–4351.
30. Smith, M. G., et al. 2007. New insights into Acinetobacter baumannii patho-
genesis revealed by high-density pyrosequencing and transposon mutagene-
sis. Genes Dev. 21:601–614.
31. Tan, C. H., J. Li, and R. L. Nation. 2007. Activity of colistin against hetero-
resistant Acinetobacter baumannii and emergence of resistance in an in vitro
pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother.
51:3413–3415.
32. Tran, A. X., et al. 2005. Resistance to the antimicrobial peptide polymyxin
requires myristoylation of Escherichia coli and Salmonella typhimurium lipid
A. J. Biol. Chem. 280:28186–28194.
33. Trent, M. S., et al. 2001. Accumulation of a polyisoprene-linked amino sugar
in polymyxin-resistant Salmonella typhimurium and Escherichia coli: struc-
tural characterization and transfer to lipid A in the periplasm. J. Biol. Chem.
276:43132–43144.
34. Urban, C., et al. 2001. Polymyxin B-resistant Acinetobacter baumannii clinical
isolate susceptible to recombinant BPI and cecropin P1. Antimicrob. Agents
Chemother. 45:994–995.
35. Vaara, M., et al. 2008. Novel polymyxin derivatives carrying only three
positive charges are effective antibacterial agents. Antimicrob. Agents Che-
mother. 52:3229–3236.
36. Vaara, M., et al. 2010. A novel polymyxin derivative that lacks the fatty acid
tail and carries only three positive charges has strong synergism with agents
excluded by the intact outer membrane. Antimicrob. Agents Chemother.
54:3341–3346.
37. Valencia, R., et al. 2009. Nosocomial outbreak of infection with pan-drug-
resistant Acinetobacter baumannii in a tertiary care university hospital. Infect.
Control Hosp. Epidemiol. 30:257–263.
38. Vaneechoutte, M., et al. 1995. Identification of Acinetobacter genomic species by
amplified ribosomal DNA restriction analysis. J. Clin. Microbiol. 33:11–15.
39. Wendt, C., B. Dietze, E. Dietz, and H. Ru¨den. 1997. Survival of Acinetobacter
baumannii on dry surfaces. J. Clin. Microbiol. 35:1394–1397.
VOL. 55, 2011 POLYMYXIN RESISTANCE IN A. BAUMANNII 3751
